COVID-19: A Review of the Proposed Pharmacological Treatments

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2020 Aug 10

PMID 32768505

Citations 51

Authors

Sarah Lam

Andrew Lombardi

Aviv Ouanounou

Affiliations

Soon will be listed here.

Abstract

The emerging pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge for healthcare systems globally. The clinical course of COVID-19 and its ability to rapidly create widespread infection has major implications, warranting vigorous infection prevention and control measures. As the confirmed number of cases has surpassed 5.6 million worldwide and continues to grow, the potential severity of the disease and its deadly complications requires urgent development of novel therapeutic agents to both prevent and treat COVID-19. Although vaccines and specific drug therapies have yet to be discovered, ongoing research and clinical trials are being conducted to investigate the efficacy of repurposed drugs for treating COVID-19. In the present review, the drug candidates that have been suggested to treat COVID-19 will be discussed. These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents. The mechanisms of action and further pharmacological properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.

Citing Articles

Prevalence, under-reporting, and epidemiological surveillance of COVID-19 in the Araguaína City of Brazil.

Oliveira M, Carvalho R, Meurer C, Rodrigues E, Dias B, Santos I PLoS One. 2024; 19(6):e0300191.

PMID: 38838042 PMC: 11152283. DOI: 10.1371/journal.pone.0300191.

Machine learning risk estimation and prediction of death in continuing care facilities using administrative data.

Shahidi F, Rennert-May E, DSouza A, Crocker A, Faris P, Leal J Sci Rep. 2023; 13(1):17708.

PMID: 37853045 PMC: 10584843. DOI: 10.1038/s41598-023-43943-9.

Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.

Akter R, Rahman M, Ahmed Z, Afrose A Heliyon. 2023; 9(6):e17478.

PMID: 37366526 PMC: 10284624. DOI: 10.1016/j.heliyon.2023.e17478.

Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.

Chaudhury S, Kaur P, Gupta D, Anand P, Chaudhary M, Tiwari S Curr Mol Med. 2023; 24(6):712-733.

PMID: 37312440 DOI: 10.2174/1566524023666230613141746.

Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study.

Almutairi A, El-Readi M, Althubiti M, Alhindi Y, Ayoub N, Alzahrani A Trop Med Infect Dis. 2023; 8(2).

PMID: 36828545 PMC: 9966436. DOI: 10.3390/tropicalmed8020129.

References

Khalili J, Zhu H, Mak N, Yan Y, Zhu Y . Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol. 2020; 92(7):740-746. PMC: 7228408. DOI: 10.1002/jmv.25798. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Verity R, Okell L, Dorigatti I, Winskill P, Whittaker C, Imai N . Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20(6):669-677. PMC: 7158570. DOI: 10.1016/S1473-3099(20)30243-7. View

Menachery V, Yount Jr B, Josset L, Gralinski L, Scobey T, Agnihothram S . Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2'-o-methyltransferase activity. J Virol. 2014; 88(8):4251-64. PMC: 3993736. DOI: 10.1128/JVI.03571-13. View

Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I . Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020; 34(2):327-331. DOI: 10.23812/CONTI-E. View

Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View

Gurwitz D . Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 81(5):537-540. PMC: 7228359. DOI: 10.1002/ddr.21656. View

Martinez M . Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother. 2020; 64(5). PMC: 7179632. DOI: 10.1128/AAC.00399-20. View

Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M . A global treatments for coronaviruses including COVID-19. J Cell Physiol. 2020; 235(12):9133-9142. PMC: 7273044. DOI: 10.1002/jcp.29785. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

12.

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

13.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

14.

Samuel C . Antiviral actions of interferons. Clin Microbiol Rev. 2001; 14(4):778-809, table of contents. PMC: 89003. DOI: 10.1128/CMR.14.4.778-809.2001. View

15.

Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T . Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020; 81(1):e21-e23. PMC: 7195393. DOI: 10.1016/j.jinf.2020.03.060. View

16.

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J . The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81(1):e13-e20. PMC: 7195158. DOI: 10.1016/j.jinf.2020.03.062. View

17.

Wu R, Wang L, Kuo H, Shannar A, Peter R, Chou P . An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020; 6(3):56-70. PMC: 7211915. DOI: 10.1007/s40495-020-00216-7. View

18.

Brown B, McCullough J . Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020; 59(3):102790. PMC: 7194745. DOI: 10.1016/j.transci.2020.102790. View

19.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

20.

Bhimraj A, Morgan R, Shumaker A, Lavergne V, Baden L, Cheng V . Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020; . PMC: 7197612. DOI: 10.1093/cid/ciaa478. View